Expanded Access to Upadacitinib

Conditions

• Atopic Dermatitis
• Crohn Disease
• Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)
• Ulcerative Colitis

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Upadacitinib — DRUG
  Upadacitinib will be administered as oral solution.

Study Details

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Key Dates

Status verified

Apr 2025

Central Contacts

• ABBVIE CALL CENTER
  844-663-3742
  [email protected]

Related Studies

• Immune Regulation in Ulcerative Colitis or Crohn s Disease
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Studies of Skin Microbes in Healthy People and in People With Skin Conditions
  Recruiting · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland
• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California